An Open-label, Randomized, Multi-center, Parallel Group, Two-arm Study to Assess the Safety, Overall Tolerability, and Antiviral Activity of Brincidofovir Versus Standard of Care for Treatment of Adenovirus Infections in High-risk Pediatric Allogeneic Hematopoietic Cell Transplant Recipients

Trial Profile

An Open-label, Randomized, Multi-center, Parallel Group, Two-arm Study to Assess the Safety, Overall Tolerability, and Antiviral Activity of Brincidofovir Versus Standard of Care for Treatment of Adenovirus Infections in High-risk Pediatric Allogeneic Hematopoietic Cell Transplant Recipients

Recruiting
Phase of Trial: Phase II

Latest Information Update: 19 May 2018

At a glance

  • Drugs Brincidofovir (Primary)
  • Indications Adenovirus infections
  • Focus Registrational; Therapeutic Use
  • Acronyms AdAPT; Study 999
  • Sponsors Chimerix
  • Most Recent Events

    • 07 May 2018 According to a Chimerix media release, the company is focusing on execution of this 141-patient trial and anticipate data read-out in the second half of 2019.
    • 01 Mar 2018 According to a Chimerix media release, data expected in the second half of 2018.
    • 05 Jan 2018 According to a Chimerix media release, the company expects to complete enrollment in the study in 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top